Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 974

Results For "C"

9939 News Found

Reforms in Ayush to boost growth: Sarbananda Sonowal
News | November 24, 2022

Reforms in Ayush to boost growth: Sarbananda Sonowal

Ayush market has reached US $18 billion from meager US $3 billion under guidance and visionary leadership of our Prime Minister


SMS Pharma revenue down 9%
News | November 15, 2022

SMS Pharma revenue down 9%

Within the API segment, ~20% of the revenues came from the domestic market and ~80% from the exports market


Aurobindo Pharma Q2 FY23 revenue down 3.4%
News | November 14, 2022

Aurobindo Pharma Q2 FY23 revenue down 3.4%

Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore


ASG Eye Hospitals enters Haryana and expands footprint in UP
Healthcare | November 10, 2022

ASG Eye Hospitals enters Haryana and expands footprint in UP

ASG is accelerating its doctor-led mission to enhance the quality of care, deliver eye care for all, and improve quality of life across India.


Lupin Q2 FY2023 revenue remains flat
News | November 10, 2022

Lupin Q2 FY2023 revenue remains flat

Investment in R&D was Rs. 337.6 crore (8.3% of sales) for Q2 FY2023 as compared to Rs. 330 crore (8.2% of sales) for Q2 FY2022.


Tina Ambani inaugurates Kokilaben Dhirubhai Ambani Hospital in Indore
Healthcare | November 03, 2022

Tina Ambani inaugurates Kokilaben Dhirubhai Ambani Hospital in Indore

KDAH Indore is a super-speciality, patient-centric, tertiary-care institution located in the Nipaniya area of Indore.


USFDA issues Form-483 for Lupin's Nagpur Unit-2
Drug Approval | October 31, 2022

USFDA issues Form-483 for Lupin's Nagpur Unit-2

The company is committed to addressing the observations at the earliest, and gaining approval for injectable manufacturing for the US


USFDA issues Form 483 for Parawada unit of Laurus Labs
Drug Approval | October 30, 2022

USFDA issues Form 483 for Parawada unit of Laurus Labs

The observation is procedural in nature and the company will address the observation within stipulated timelines.


Quizartinib granted priority review in the U.S.
Drug Approval | October 26, 2022

Quizartinib granted priority review in the U.S.

Submission based on QuANTUM-First results showing quizartinib plus chemotherapy significantly improved overall survival compared to chemotherapy alone


Aarti Drugs Q2 FY23 revenue up 19%; Profit down 5.6%
News | October 21, 2022

Aarti Drugs Q2 FY23 revenue up 19%; Profit down 5.6%

Around 62% of the revenues came from the domestic market and 38% from the exports market for Q2 FY23 for a standalone business